Mer­ck KGaA to fo­cus on ‘ex­ter­nal in­no­va­tion’ as it ex­its BTK in­hibitor race

Mer­ck KGaA is re­vamp­ing its R&D ef­forts as it in­creas­es fo­cus on li­cens­ing deals rather than its in­ter­nal pipeline. Sev­er­al months af­ter a Phase III dis­ap­point­ment, its BTK in­hibitor is out the door, leav­ing the com­pa­ny with just two late-stage can­di­dates.

“We have stopped the [evo­bru­ti­nib] pro­gram — we are not go­ing to ex­plore any oth­er op­tion,” CEO Belén Gar­i­jo said dur­ing its full-year earn­ings call with the me­dia. “We have to be very dis­ci­plined with our cap­i­tal al­lo­ca­tion, and now we will fo­cus on the oth­er as­sets that we have in Phase III to move them for­ward.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER